Lexeo Therapeutics Files 2025 Proxy Statement
Ticker: LXEO · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Lexeo Therapeutics filed its proxy statement for 2024. Shareholders vote on directors & pay.
AI Summary
Lexeo Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 28, 2025, for the fiscal year ending December 31, 2024. The filing provides details regarding the company's annual meeting of stockholders and related matters, including the election of directors and executive compensation. The company is involved in the development of gene therapies.
Why It Matters
This filing is crucial for shareholders as it outlines proposals for the annual meeting, including director elections and executive compensation, which directly impact the company's governance and future direction.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that provides information to shareholders and does not contain new material events or significant financial disclosures.
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- 0000950170-25-059375 (filing_id) — Accession Number
- 20250428 (date) — Filing Date
- 20241231 (date) — Fiscal Year End
- 345 PARK AVENUE SOUTH (address) — Company Business Address
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming annual or special meeting. It provides detailed information about matters to be voted on, such as director elections, executive compensation, and other corporate proposals.
When was this specific DEF 14A filing made by Lexeo Therapeutics, Inc.?
Lexeo Therapeutics, Inc. filed this definitive proxy statement on April 28, 2025.
What fiscal year does this proxy statement cover?
This proxy statement covers the fiscal year ending December 31, 2024.
What is Lexeo Therapeutics, Inc.'s primary business according to the filing's SIC code?
According to the filing's Standard Industrial Classification (SIC) code [2836], Lexeo Therapeutics, Inc. is primarily involved in Biological Products (No Diagnostic Substances).
Where is Lexeo Therapeutics, Inc. located?
Lexeo Therapeutics, Inc.'s business and mailing address is 345 Park Avenue South, Floor 6, New York, NY 10010.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Lexeo Therapeutics, Inc. (LXEO).